HIV protease inhibitors-induced atherosclerosis: Prevention by α-tocopherol

Adelina Munteanu, Roberta Ricciarelli, Jean Marc Zingg

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Prolonged treatments with inhibitors of human immunodeficiency (HIV)-encoded protease (ARPI) have been reported to induce early atherosclerotic events. Our in vitro study indicates that α-tocopherol may prevent drug-induced premature atherosclerosis since it interferes with CD36 scavenger receptor over-expression induced by ritonavir in monocytes. The mechanism of CD36 upregulation by ritonavir involves inhibition of the ubiquitin-proteasome system and α-tocopherol is able to normalize proteasome activity. These findings suggest that ARPI combined with early α-tocopherol supplementation may decrease the drug-induced atherosclerotic risk.

Original languageEnglish (US)
Pages (from-to)629-631
Number of pages3
JournalIUBMB life
Issue number10
StatePublished - Oct 2004
Externally publishedYes


  • Atherosclerosis
  • CD36
  • Proteasome
  • Ritonavir
  • Scavenger receptor
  • Tocopherol
  • Vitamin E

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'HIV protease inhibitors-induced atherosclerosis: Prevention by α-tocopherol'. Together they form a unique fingerprint.

Cite this